Raltegravir: a new choice in HIV and new chances for research
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference10 articles.
1. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009
2. Raltegravir: an integrase inhibitor for HIV-1;Evering;Expert Opin Investig Drugs,2008
3. Integrase inhibitors for the treatment of HIV infection;Pace;Curr Opin Drug Discov Devel,2008
4. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies;Lancet,2008
5. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018–2020);Infection;2021-07-19
2. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections;Journal of Controlled Release;2020-05
3. Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products;The Open AIDS Journal;2017-04-26
4. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell–Cell HIV Transmission;Molecular Pharmaceutics;2015-11-18
5. Oxidative Stress and Human Immunodeficiency Virus Type 1 (HIV-1) Infection;Role of Oxidative Stress in Chronic Diseases;2014-02-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3